Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children

Centre Hospitalier Universitaire de Saint Etienne

Status: Enrolling

Conditions: Myopia; Children

Treatments: Other: data collection

Study type: Observational

Funder types: Other

Identifiers

NCT04252989

IRBN962019/CHUSTE

Details and patient eligibility

About

Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic.

ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising.

The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017.

Few clinical data have been published so far concerning the French population.

The investigators would like to build a database so that the investigators can publish our results and share our experience.

Enrollment: 50 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children with active myopia treated with ATROPINE 0.01% eye drops
• patient affiliated with a social security organization
• agreement of both parents

Exclusion criteria

• non compliance with treatment

Trial design

50 participants in 1 patient group

Children with active myopia treated with ATROPINE eye drops

Treatment:

Other: data collection